Itraconazol Germed

Itraconazole, the active ingredient in Itraconazol Germed, is an azole antifungal presented as an oral tablet for oral use. It treats a range of fungal infections including skin, nail and systemic mycoses in adult patients.

GNH USA supplies Itraconazol Germed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Itraconazole is used to treat fungal infections that affect the skin, nails and internal organs.

- Dermatophytosis: eradicates dermatophyte fungi causing ringworm and related skin lesions. - Onychomycosis: clears fungal infection of the toenails and fingernails. - Blastomycosis: treats systemic infection caused by Blastomyces dermatitidis. - Histoplasmosis: combats disseminated disease due to Histoplasma capsulatum. - Aspergillosis: manages invasive disease caused by Aspergillus species. - Other systemic mycoses: effective against a broad spectrum of deep fungal infections.

Common side effects are generally mild and may resolve without intervention.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Abdominal pain: intermittent discomfort in the abdomen. - Diarrhea: loose stools occurring occasionally. - Rash: mild skin erythema or itching. - Elevated liver enzymes: transient increase in hepatic transaminases.

Serious or Rare Side Effects: - Hepatotoxicity: severe liver injury requiring monitoring. - Congestive heart failure: fluid retention and reduced cardiac function. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Visual disturbances: blurred vision or photophobia. - Severe hypotension: sudden drop in blood pressure. - Anaphylaxis: rare systemic allergic reaction.

Before initiating therapy, consider the following precautions. - Liver function: assess baseline hepatic enzymes and monitor periodically. - Cardiac status: avoid in patients with existing heart failure. - Drug interactions: review concomitant medications for potential CYP3A4 interactions. - Pregnancy and lactation: use only if potential benefit outweighs risk, as safety data are limited. - Renal impairment: adjust dosing in severe renal dysfunction as advised by prescriber. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Itraconazole has a notable interaction profile that requires careful management.

Major Interactions (Avoid): - Rifampin: induces CYP3A4, markedly reducing itraconazole exposure. - St. John’s wort: strong CYP3A4 inducer, decreases therapeutic levels. - Certain antiretrovirals (e.g., protease inhibitors): may cause toxic accumulation. - Ketoconazole: concurrent use increases risk of hepatotoxicity. - Certain statins (e.g., simvastatin, lovastatin): heightened risk of myopathy.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, monitor INR. - Phenytoin: may lower itraconazole concentrations. - Midazolam: increased sedation, adjust dose as needed. - Calcium channel blockers (e.g., verapamil): monitor for hypotension. - Digoxin: potential increase in serum levels, observe cardiac function.